An Early Phase 1 interventional study of [18F]F-PSMA-N5 and [18F]F-PSMA-1007 in Prostate Cancer and PET/CT, sponsored by Anhui Provincial Hospital. Recruiting at 1 site in China. Open to male participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-06-17.
Sponsored by Anhui Provincial Hospital · Early Phase 1, Interventional, and Diagnostic
To prospectively evaluate the radiodrug biodistribution of a novel PET imaging agent [18F]F-PSMA-N5 in different organs of prostate cancer patients and its diagnostic efficacy in the diagnosis, recurrence and metastasis of prostate cancer, and to compare with [18F]F-PSMA-1007.
[18F]F-PSMA-N5 PET/CT was used for initial assessment of prostate cancer or detection of recurrence. The maximum standardized uptake value (SUVmax) was used to evaluate tumor uptake. The sensitivity, specificity, the number and accuracy of lesions identified and the distribution of lesions in each organ were calculated and compared with those of [18F]F-PSMA-1007 PET/CT.
6,370 studies on the registry are indexed under Prostatic Neoplasms; 1,399 are open to participants now.
This study's planned enrollment of 30 is below the median of 58 across 4,822 interventional studies indexed under Prostatic Neoplasms.
Browse Prostatic Neoplasms studies →Anhui Provincial Hospital is the lead sponsor of 129 studies on the registry; 95 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Subjects PET/CT imaging: On any two days for two consecutive weeks, each subject underwent a PET/ CT scan after intravenous injection of \[18F\]F-PSMA-N5 and \[18F\]F-PSMA-1007.
Drug: [18F]F-PSMA-N5 · Drug: [18F]F-PSMA-1007
Each subject receive a single intravenous injection of \[18F\]F-PSMA-N5, and undergo PET/CT imaging within the specificed time.
Also known as: [18F]F-PSMA-N5 injection
Each subject receive a single intravenous injection of \[18F\]F-PSMA-1007, and undergo PET/CT imaging within the specificed time.
Also known as: [18F]F-PSMA-1007 injection
Standard uptake value(SUV)
Standard uptake value(SUV) of \[18F\]F-PSMA-N5 and \[18F\]F-PSMA-1007 for each target lesion of subjects.
Time frame: 30 days
Diagnostic efficacy
The sensitivity, specificity and accuracy of \[18F\]F-PSMA-N5 and \[18F\]F-PSMA-1007 PET/CT were calculated.
Time frame: 30 days
Number of lesions
The number of lesions detected by \[18F\]F-PSMA-N5 and \[18F\]F-PSMA-1007 PET/CT.
Time frame: 30 days
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Anhui Provincial Hospital